Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 35122 | 52 | 35.5 | 65% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 3080 | 1890 | ANTISECRETORY FACTOR//LOTEPREDNOL ETABONATE//METADOXINE |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | L DOPA PRODRUGS | Author keyword | 2 | 67% | 4% | 2 |
| 2 | 6 HYDROXYDOPAMINE 6 OHDA LESIONED RAT | Author keyword | 1 | 100% | 4% | 2 |
| 3 | PROXIMAGEN NEUROSCI PLC | Address | 1 | 100% | 4% | 2 |
| 4 | BBB PERMEATION | Author keyword | 1 | 50% | 2% | 1 |
| 5 | L DOPA PRODRUG | Author keyword | 1 | 50% | 2% | 1 |
| 6 | LEVODOPA ETHYL ESTER | Author keyword | 1 | 50% | 2% | 1 |
| 7 | PRODRUG APPROACH | Author keyword | 1 | 50% | 2% | 1 |
| 8 | ANTIPARKINSON | Author keyword | 1 | 22% | 4% | 2 |
| 9 | A BETA1 42 AGGREGATION | Author keyword | 0 | 33% | 2% | 1 |
| 10 | CESI STUDI INVECCHIAMENTO | Address | 0 | 33% | 2% | 1 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | L DOPA PRODRUGS | 2 | 67% | 4% | 2 | Search L+DOPA+PRODRUGS | Search L+DOPA+PRODRUGS |
| 2 | 6 HYDROXYDOPAMINE 6 OHDA LESIONED RAT | 1 | 100% | 4% | 2 | Search 6+HYDROXYDOPAMINE+6+OHDA+LESIONED+RAT | Search 6+HYDROXYDOPAMINE+6+OHDA+LESIONED+RAT |
| 3 | BBB PERMEATION | 1 | 50% | 2% | 1 | Search BBB+PERMEATION | Search BBB+PERMEATION |
| 4 | L DOPA PRODRUG | 1 | 50% | 2% | 1 | Search L+DOPA+PRODRUG | Search L+DOPA+PRODRUG |
| 5 | LEVODOPA ETHYL ESTER | 1 | 50% | 2% | 1 | Search LEVODOPA+ETHYL+ESTER | Search LEVODOPA+ETHYL+ESTER |
| 6 | PRODRUG APPROACH | 1 | 50% | 2% | 1 | Search PRODRUG+APPROACH | Search PRODRUG+APPROACH |
| 7 | ANTIPARKINSON | 1 | 22% | 4% | 2 | Search ANTIPARKINSON | Search ANTIPARKINSON |
| 8 | A BETA1 42 AGGREGATION | 0 | 33% | 2% | 1 | Search A+BETA1+42+AGGREGATION | Search A+BETA1+42+AGGREGATION |
| 9 | IMIDAZOPYRIDINE COMPOUNDS | 0 | 33% | 2% | 1 | Search IMIDAZOPYRIDINE+COMPOUNDS | Search IMIDAZOPYRIDINE+COMPOUNDS |
| 10 | PC3 PROSTATE CANCER CELLS | 0 | 33% | 2% | 1 | Search PC3+PROSTATE+CANCER+CELLS | Search PC3+PROSTATE+CANCER+CELLS |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | CODRUGS | 6 | 80% | 8% | 4 |
| 2 | L DOPA PRODRUGS | 1 | 40% | 4% | 2 |
| 3 | L 3 3 HYDROXY 4 PIVALOYLOXYPHENYLALANINE | 1 | 50% | 2% | 1 |
| 4 | DEPLETION IN VITRO | 0 | 33% | 2% | 1 |
| 5 | SUBTHALAMIC NUCLEUS LESION | 0 | 33% | 2% | 1 |
| 6 | MEMBRANE PERMEABILITY ASSAY | 0 | 10% | 6% | 3 |
| 7 | PEPTIDE CARRIER SYSTEM | 0 | 25% | 2% | 1 |
| 8 | LEVODOPA INFUSIONS | 0 | 20% | 2% | 1 |
| 9 | POTENTIAL PRODRUG | 0 | 20% | 2% | 1 |
| 10 | D 1 RECEPTOR AGONIST | 0 | 11% | 4% | 2 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
|---|---|---|---|---|
| L-Dopa Prodrugs: An Overview of Trends for Improving Parkinson's Disease Treatment | 2011 | 9 | 69 | 32% |
| Designing prodrugs for the treatment of Parkinson's disease | 2012 | 6 | 97 | 23% |
| Antiparkinson Prodrugs | 2008 | 20 | 67 | 19% |
| Recent Advances in the Treatment of Neurodegenerative Diseases Based on GSH Delivery Systems | 2012 | 16 | 90 | 8% |
| The creation of drugs to be transported to the brain | 1998 | 0 | 36 | 11% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | PROXIMAGEN NEUROSCI PLC | 1 | 100% | 3.8% | 2 |
| 2 | CESI STUDI INVECCHIAMENTO | 0 | 33% | 1.9% | 1 |
| 3 | FARMACOL SPERIMENTALE | 0 | 33% | 1.9% | 1 |
| 4 | NDRC | 0 | 15% | 3.8% | 2 |
| 5 | SECT CHIETI | 0 | 14% | 1.9% | 1 |
| 6 | DIPARTIMENTO NEUROSCI IMAGINGIIM | 0 | 100% | 1.9% | 1 |
| 7 | FARMACO CHIM TOSSICOL | 0 | 100% | 1.9% | 1 |
| 8 | SANGGYE BAEK HOSP | 0 | 100% | 1.9% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000270990 | BUDIPINE//4 SUBSTITUTED ANILINES//LONG TERM ELECTROMYOGRAPHY |
| 2 | 0.0000237724 | METADOXINE//OENANTHE JAVANICA//PERSICARIN |
| 3 | 0.0000237012 | DIFFUSION CELL EXPERIMENTS//TRANSFORMED POTTS GUY EQUATION//ROBERTS SLOAN EQUATION |
| 4 | 0.0000215610 | METHYLDOPA//CARBIDOPA//MULTIWALL CARBON NANOTUBES PASTE ELECTRODE |
| 5 | 0.0000192811 | MOTOR FLUCTUATIONS//LEVODOPA//DYSKINESIA |
| 6 | 0.0000151796 | IODOQUINOL//CHINOFORM//DIIODOQUIN |
| 7 | 0.0000147152 | GLOBAL CHEM SCI//2 AMINOTETRALIN//2 AMINOTETRALINS |
| 8 | 0.0000130536 | INNER BLOOD RETINAL BARRIER//RETINAL CAPILLARY ENDOTHELIAL CELLS//DRUG DISPOSIT PHARMACOKINET |
| 9 | 0.0000125653 | ANTISECRETORY FACTOR//DEITERS NEURON//SPECIALLY PROCESSED CEREALS |
| 10 | 0.0000114422 | BRAIN TARGETING//SMART DRUG DELIVERY//ANGIOPEP 2 |